Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases - PubMed (original) (raw)

Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases

K Gijbels et al. J Clin Invest. 1994 Dec.

Abstract

Gelatinases, belonging to the matrix metalloproteases, contribute to tissue destruction in inflammatory demyelinating disorders of the central nervous system such as multiple sclerosis. We used experimental autoimmune encephalomyelitis (EAE) as an animal model to evaluate the effect of a hydroxamate matrix metalloprotease inhibitor (GM 6001) on inflammatory demyelination. A single dose of the inhibitor, given intraperitoneally, provided sufficient levels in the cerebrospinal fluid of animals with EAE to induce at least a partial inhibition of the gelatinase activity in the cerebrospinal fluid. When administered daily either from the time of disease induction or from the onset of clinical signs, GM 6001 suppressed the development or reversed clinical EAE in a dose-dependent way, respectively. Animals returned to the same clinical course as the nontreated group after cessation of treatment. Animals treated from the onset of clinical signs had normal permeability of the blood-brain barrier, compared with the enhanced permeability in nontreated animals. These results indicate that matrix metalloprotease inhibition can reverse ongoing EAE. This effect appears to be mediated mainly through restoration of the damaged blood-brain barrier in the inflammatory phase of the disease, since, the degree of demyelination and inflammation did not differ between the treatment groups.

PubMed Disclaimer

Similar articles

• Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice.
  Thorne M, Moore CS, Robertson GS. Thorne M, et al. J Neuroimmunol. 2009 Jun 25;211(1-2):92-100. doi: 10.1016/j.jneuroim.2009.04.003. Epub 2009 May 9. J Neuroimmunol. 2009. PMID: 19428125
• The interrelationship of alpha4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis.
  Graesser D, Mahooti S, Haas T, Davis S, Clark RB, Madri JA. Graesser D, et al. Lab Invest. 1998 Nov;78(11):1445-58. Lab Invest. 1998. PMID: 9840619
• Angiopoietin-1 ameliorates inflammation-induced vascular leakage and improves functional impairment in a rat model of acute experimental autoimmune encephalomyelitis.
  Jiang H, Zhang F, Yang J, Han S. Jiang H, et al. Exp Neurol. 2014 Nov;261:245-57. doi: 10.1016/j.expneurol.2014.05.013. Epub 2014 May 20. Exp Neurol. 2014. PMID: 24852101
• Mechanisms and suppression of inflammatory demyelination.
  Norton WT, Brosnan CF, Cammer W, Goldmuntz EA. Norton WT, et al. Acta Neurobiol Exp (Wars). 1990;50(4-5):225-35. Acta Neurobiol Exp (Wars). 1990. PMID: 2130645 Review.
• Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
  Kieseier BC, Seifert T, Giovannoni G, Hartung HP. Kieseier BC, et al. Neurology. 1999 Jul 13;53(1):20-5. doi: 10.1212/wnl.53.1.20. Neurology. 1999. PMID: 10408531 Review.

Cited by

• Demyelination: the role of reactive oxygen and nitrogen species.
  Smith KJ, Kapoor R, Felts PA. Smith KJ, et al. Brain Pathol. 1999 Jan;9(1):69-92. doi: 10.1111/j.1750-3639.1999.tb00212.x. Brain Pathol. 1999. PMID: 9989453 Free PMC article. Review.
• Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790.
  Hewson AK, Smith T, Leonard JP, Cuzner ML. Hewson AK, et al. Inflamm Res. 1995 Aug;44(8):345-9. doi: 10.1007/BF01796266. Inflamm Res. 1995. PMID: 8581522
• Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix.
  Stetler-Stevenson WG. Stetler-Stevenson WG. Am J Pathol. 1996 May;148(5):1345-50. Am J Pathol. 1996. PMID: 8623905 Free PMC article. Review. No abstract available.
• A New Signaling Pathway for HCV Inhibition by Estrogen: GPR30 Activation Leads to Cleavage of Occludin by MMP-9.
  Ulitzky L, Lafer MM, KuKuruga MA, Silberstein E, Cehan N, Taylor DR. Ulitzky L, et al. PLoS One. 2016 Jan 5;11(1):e0145212. doi: 10.1371/journal.pone.0145212. eCollection 2016. PLoS One. 2016. PMID: 26731262 Free PMC article.
• Matrix metalloproteinase inhibition enhances the rate of nerve regeneration in vivo by promoting dedifferentiation and mitosis of supporting schwann cells.
  Liu H, Kim Y, Chattopadhyay S, Shubayev I, Dolkas J, Shubayev VI. Liu H, et al. J Neuropathol Exp Neurol. 2010 Apr;69(4):386-95. doi: 10.1097/NEN.0b013e3181d68d12. J Neuropathol Exp Neurol. 2010. PMID: 20448483 Free PMC article.

References

1. 1. Adv Immunol. 1991;49:357-79 - PubMed
2. 1. J Biol Chem. 1990 Dec 15;265(35):21929-34 - PubMed
3. 1. Biochemistry. 1992 Aug 11;31(31):7152-4 - PubMed
4. 1. Brain Res. 1992 Apr 3;576(2):203-7 - PubMed
5. 1. Neuropathol Appl Neurobiol. 1992 Aug;18(4):319-34 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Society for Clinical Investigation
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information